分枝杆菌菌株的核糖体糖基化作用作为利福平失活的一种新机制。
Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation.
作者信息
Dabbs E R, Yazawa K, Mikami Y, Miyaji M, Morisaki N, Iwasaki S, Furihata K
机构信息
Division of Experimental Chemotherapy, Chiba University, Japan.
出版信息
Antimicrob Agents Chemother. 1995 Apr;39(4):1007-9. doi: 10.1128/AAC.39.4.1007.
Abstract
Several fast-growing Mycobacterium strains were found to inactivate rifampin. Two inactivated compounds (RIP-Ma and RIP-Mb) produced by these organisms were different from previously reported derivatives, i.e., phosphorylated or glucosylated derivatives, of the antibiotic. The structures of RIP-Ma and RIP-Mb were determined to be those of 3-formyl-23-[O-(alpha-D-ribofuranosyl)]rifamycin SV and 23-[O-(alpha-D-ribofuranosyl)]rifampin, respectively. To our knowledge, this is the first known example of ribosylation as a mechanism of antibiotic inactivation.
摘要
发现几种快速生长的分枝杆菌菌株可使利福平失活。这些菌株产生的两种失活化合物（RIP-Ma和RIP-Mb）与先前报道的该抗生素的衍生物（即磷酸化或糖基化衍生物）不同。RIP-Ma和RIP-Mb的结构分别确定为3-甲酰基-23-[O-(α-D-呋喃核糖基)]利福霉素SV和23-[O-(α-D-呋喃核糖基)]利福平的结构。据我们所知，这是核糖基化作为抗生素失活机制的首个已知实例。
相似文献
1
Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation.分枝杆菌菌株的核糖体糖基化作用作为利福平失活的一种新机制。
Antimicrob Agents Chemother. 1995 Apr;39(4):1007-9. doi: 10.1128/AAC.39.4.1007.
2
Structure determination of ribosylated rifampicin and its derivative: new inactivated metabolites of rifampicin by mycobacterial strains.核糖基化利福平及其衍生物的结构测定：分枝杆菌菌株产生的利福平新的失活代谢产物
J Antibiot (Tokyo). 1995 Nov;48(11):1299-303. doi: 10.7164/antibiotics.48.1299.
3
Inactivation of rifampin by Nocardia brasiliensis.巴西诺卡菌对利福平的灭活作用。
Antimicrob Agents Chemother. 1993 Jun;37(6):1313-7. doi: 10.1128/AAC.37.6.1313.
4
Inactivated products of rifampicin by pathogenic Nocardia spp.: structures of glycosylated and phosphorylated metabolites of rifampicin and 3-formylrifamycin SV.
J Antibiot (Tokyo). 1993 Oct;46(10):1605-10. doi: 10.7164/antibiotics.46.1605.
5
Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis.耻垢分枝杆菌对利福平核糖基化失活途径中一种新中间体的鉴定与表征。
Microb Drug Resist. 1999 Winter;5(4):259-64. doi: 10.1089/mdr.1999.5.259.
6
ADP-ribosylation as an intermediate step in inactivation of rifampin by a mycobacterial gene.ADP-核糖基化作为分枝杆菌基因使利福平失活的中间步骤。
Antimicrob Agents Chemother. 1999 Jan;43(1):181-4. doi: 10.1128/AAC.43.1.181.
7
Phosphorylative inactivation of rifampicin by Nocardia otitidiscaviarum.
J Antimicrob Chemother. 1994 Jun;33(6):1127-35. doi: 10.1093/jac/33.6.1127.
8
Structures of ADP-ribosylated rifampicin and its metabolite: intermediates of rifampicin-ribosylation by Mycobacterium smegmatis DSM43756.ADP-核糖基化利福平及其代谢产物的结构：耻垢分枝杆菌DSM43756对利福平进行核糖基化的中间体
J Antibiot (Tokyo). 2000 Mar;53(3):269-75. doi: 10.7164/antibiotics.53.269.
9
Light inhibits rifampicin inactivation and reduces rifampicin resistance due to a cloned mycobacterial ADP-ribosylation gene.光照可抑制利福平失活，并降低因克隆的分枝杆菌ADP-核糖基化基因导致的利福平耐药性。
FEMS Microbiol Lett. 2000 Jan 1;182(1):105-9. doi: 10.1111/j.1574-6968.2000.tb08882.x.
10
Permeability barrier to rifampin in mycobacteria.分枝杆菌对利福平的通透性屏障
Antimicrob Agents Chemother. 1977 May;11(5):773-9. doi: 10.1128/AAC.11.5.773.
引用本文的文献
1
General ADP-Ribosylation Mechanism Based on the Structure of ADP-Ribosyltransferase-Substrate Complexes.基于 ADP-核糖基转移酶-底物复合物结构的通用 ADP-核糖基化机制。
Toxins (Basel). 2024 Jul 11;16(7):313. doi: 10.3390/toxins16070313.
2
Functional analysis of bacterial genes accidentally packaged in rhizospheric phageome of the wild plant species .野生植物根际噬菌体组中意外包装的细菌基因的功能分析
Saudi J Biol Sci. 2023 Oct;30(10):103789. doi: 10.1016/j.sjbs.2023.103789. Epub 2023 Aug 26.
3
Beyond protein modification: the rise of non-canonical ADP-ribosylation.超越蛋白质修饰：非典型 ADP-核糖基化的兴起。
Biochem J. 2022 Feb 17;479(4):463-477. doi: 10.1042/BCJ20210280.
4
Rifamycin antibiotics and the mechanisms of their failure.利福霉素类抗生素及其耐药机制。
J Antibiot (Tokyo). 2021 Nov;74(11):786-798. doi: 10.1038/s41429-021-00462-x. Epub 2021 Aug 16.
5
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.阻断细菌萘氢醌氧化和 ADP-核糖基化可提高利福霉素类药物对脓肿分枝杆菌的活性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0097821. doi: 10.1128/AAC.00978-21.
6
Re-sensitization of to Rifampicin Using CRISPR Interference Demonstrates Its Utility for the Study of Non-essential Drug Resistance Traits.使用CRISPR干扰对利福平进行再敏化证明了其在非必需耐药性状研究中的效用。
Front Microbiol. 2021 Feb 1;11:619427. doi: 10.3389/fmicb.2020.619427. eCollection 2020.
7
Engineering Af1521 improves ADP-ribose binding and identification of ADP-ribosylated proteins.工程化 Af1521 提高了 ADP-ribose 的结合能力，并鉴定了 ADP-ribosylated 蛋白质。
Nat Commun. 2020 Oct 15;11(1):5199. doi: 10.1038/s41467-020-18981-w.
8
DNA ADP-Ribosylation Stalls Replication and Is Reversed by RecF-Mediated Homologous Recombination and Nucleotide Excision Repair.DNA ADP-核糖基化使复制停滞，并通过 RecF 介导的同源重组和核苷酸切除修复得到逆转。
Cell Rep. 2020 Feb 4;30(5):1373-1384.e4. doi: 10.1016/j.celrep.2020.01.014.
9
Antibiotic resistance genes in the Actinobacteria phylum.放线菌门中的抗生素耐药基因。
Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1599-1624. doi: 10.1007/s10096-019-03580-5. Epub 2019 Jun 27.
10
Integrative metagenomic and biochemical studies on rifamycin ADP-ribosyltransferases discovered in the sediment microbiome.整合宏基因组学和生物化学研究揭示了沉积物微生物组中发现的利福霉素 ADP-核糖基转移酶。
Sci Rep. 2018 Aug 14;8(1):12143. doi: 10.1038/s41598-018-30547-x.
本文引用的文献
1
Molecular basis of rifampin resistance in Mycobacterium leprae.麻风分枝杆菌中利福平耐药性的分子基础。
Antimicrob Agents Chemother. 1993 Mar;37(3):414-8. doi: 10.1128/AAC.37.3.414.
2
Inactivation of rifampin by Nocardia brasiliensis.巴西诺卡菌对利福平的灭活作用。
Antimicrob Agents Chemother. 1993 Jun;37(6):1313-7. doi: 10.1128/AAC.37.6.1313.
3
Inactivated products of rifampicin by pathogenic Nocardia spp.: structures of glycosylated and phosphorylated metabolites of rifampicin and 3-formylrifamycin SV.
J Antibiot (Tokyo). 1993 Oct;46(10):1605-10. doi: 10.7164/antibiotics.46.1605.
4
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.结核分枝杆菌中利福平耐药性突变的检测
Lancet. 1993 Mar 13;341(8846):647-50. doi: 10.1016/0140-6736(93)90417-f.
5
Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures and in clinical specimens.在分枝杆菌培养物和临床标本中检测编码对利福平耐药性的基因位点。
Diagn Microbiol Infect Dis. 1994 Apr;18(4):219-27. doi: 10.1016/0732-8893(94)90024-8.
6
Characterization of rifampin-resistance in pathogenic mycobacteria.致病性分枝杆菌中利福平耐药性的特征分析。
Antimicrob Agents Chemother. 1994 Oct;38(10):2380-6. doi: 10.1128/AAC.38.10.2380.
7
Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species.致病性诺卡氏菌属对大环内酯类抗生素红霉素、麦迪霉素和罗他霉素的灭活作用
Antimicrob Agents Chemother. 1994 Sep;38(9):2197-9. doi: 10.1128/AAC.38.9.2197.
8
Microbial glycosylation of erythromycin A.红霉素A的微生物糖基化作用。
Antimicrob Agents Chemother. 1989 Dec;33(12):2089-91. doi: 10.1128/AAC.33.12.2089.
9
Synthesis and biological activity of some derivatives of rifamycin P.利福霉素P的某些衍生物的合成及生物活性
J Med Chem. 1990 May;33(5):1470-6. doi: 10.1021/jm00167a029.
10
Cloning of nocardioform DNA conferring the ability to inactivate rifampicin.
FEMS Microbiol Lett. 1991 Apr 15;63(2-3):247-50. doi: 10.1016/0378-1097(91)90093-p.
Zotero 插件